Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,908 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group.
Ueda T, Miyawaki S, Asou N, Kuraishi Y, Hiraoka A, Kuriyama K, Minami S, Ohshima T, Ino T, Tamura J, Kanamaru A, Nishikawa K, Tanimoto M, Oh H, Saito K, Nagata K, Naoe T, Yamada O, Urasaki Y, Sakura T, Ohno R. Ueda T, et al. Among authors: oh h. Int J Hematol. 1998 Oct;68(3):279-89. doi: 10.1016/s0925-5710(98)00075-9. Int J Hematol. 1998. PMID: 9846012 Clinical Trial.
Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group.
Takeshita A, Sakamaki H, Miyawaki S, Kobayashi T, Kuriyama K, Yamada O, Oh H, Takenaka T, Asou N, Ohno R. Takeshita A, et al. Among authors: oh h. Cancer. 1995 Aug 15;76(4):602-8. doi: 10.1002/1097-0142(19950815)76:4<602::aid-cncr2820760410>3.0.co;2-l. Cancer. 1995. PMID: 8625153
Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R. Asou N, et al. Among authors: oh h. J Clin Oncol. 1998 Jan;16(1):78-85. doi: 10.1200/JCO.1998.16.1.78. J Clin Oncol. 1998. PMID: 9440726
Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
Miyawaki S, Kobayashi T, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Omoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Ueda T, Tomonaga M, Ohno R, et al. Miyawaki S, et al. Among authors: oh h. Int J Hematol. 1999 Jul;70(1):56-7. Int J Hematol. 1999. PMID: 10446497 Clinical Trial. No abstract available.
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R, et al. Miyawaki S, et al. Among authors: oh h. Int J Hematol. 1999 Aug;70(2):97-104. Int J Hematol. 1999. PMID: 10497848 Clinical Trial.
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R, et al. Kobayashi T, et al. Among authors: oh h. J Clin Oncol. 1996 Jan;14(1):204-13. doi: 10.1200/JCO.1996.14.1.204. J Clin Oncol. 1996. PMID: 8558199 Clinical Trial.
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. Kiyoi H, et al. Among authors: oh h. Blood. 1999 May 1;93(9):3074-80. Blood. 1999. PMID: 10216104 Free article. Clinical Trial.
Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).
Asou N, Adachi K, Tamura U, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama U, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake H, Ohno R. Asou N, et al. Among authors: oh h. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S65-71. doi: 10.1007/s002800100308. Cancer Chemother Pharmacol. 2001. PMID: 11587370 Clinical Trial.
5,908 results